Stay updated with breaking news from Maher Masoud. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) CEO Maher Masoud acquired 70,443 shares of the stock in a transaction dated Monday, June 10th. The stock was bought at an average cost of $4.90 per share, with a total value of $345,170.70. Following the completion of the purchase, the chief executive officer now owns 100,000 shares […]
IN BRIEF: MaxCyte inks deal with Legend Biotech for tech supply | Financial News
Investegate announcements from Signing of Strategic Platform License
MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing next-generation cell therapeutics - Inks strategic platform license agreement with Legend Biotech...
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs...